<DOC>
	<DOCNO>NCT01650805</DOCNO>
	<brief_summary>The purpose study compare efficacy ponatinib imatinib patient newly diagnose chronic myeloid leukemia ( CML ) chronic phase .</brief_summary>
	<brief_title>Ponatinib Newly Diagnosed Chronic Myeloid Leukemia ( CML ) ( EPIC )</brief_title>
	<detailed_description>This multicenter , international , phase 3 trial test hypothesis ponatinib effective treatment newly diagnose CP-CML patient compare standard imatinib . Patients randomize 1:1 fashion , stratify Sokal risk score diagnosis ( low , intermediate , high ) , receive daily oral administration either ponatinib imatinib . Efficacy measure include molecular , cytogenetic , hematologic response rate various timepoints ; time , duration , durability response ; survival follow-up . Safety measure include clinical laboratory testing , adverse event monitoring , vital sign , physical exam , ECGs , ECHOs . Other measure include two patient-reported health outcome questionnaire ( FACT-Leu EQ-5D-5L ) , determination mutation status , , ponatinib , measurement steady-state plasma concentration . Accrual expect take approximately 2 year , patient follow survival 8 year last patient 's first dose ; therefore , patient participation may last 10 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Ponatinib</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>1 . CP CML within 6 month diagnosis CPCML define ( ) &lt; 15 % blast bone marrow ; ( ii ) &lt; 30 % blast plus promyelocytes bone marrow ; ( iii ) &lt; 20 % basophils peripheral blood ; ( iv ) ≥100 × 10^9/L platelet ( ≥100,000/mm^3 ) ; ( v ) No evidence extramedullary disease except hepatosplenomegaly ; AND ( vi ) No prior diagnosis APCML BPCML 2 . Cytogenetic assessment must demonstrate BCRABL fusion presence ( 9 ; 22 ) Philadelphia chromosome ( ) Variant translocation allow provide assessable cytogenetic response utilizing conventional cytogenetic technique ; ( b ) Conventional chromosome banding must perform ; AND ( c ) A minimum 20 metaphase must assessable entry 3 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 , 1 , 2 4 . Adequate hepatic function define follow criterion : ( ) Total serum bilirubin ≤1.5 x upper limit normal ( ULN ) , unless due Gilbert 's syndrome ; ( b ) Alanine aminotransferase ( ALT ) ≤2.5 × ULN ; AND ( c ) Aspartate aminotransferase ( AST ) ≤2.5 × ULN 5 . Adequate renal function define defined serum creatinine &lt; 1.5 x ULN 6 . Adequate pancreatic function define serum lipase amylase ≤1.5 × ULN 1 . Received prior imatinib therapy 2 . Received prior dasatinib therapy 3 . Received prior nilotinib therapy 4 . Received , CML , systemic anticancer therapy , experimental therapy , radiation therapy exception anagrelide hydroxyurea 5 . Major surgery within 28 day prior initiate therapy 6 . History bleed disorder unrelated CML 7 . History acute pancreatitis within 1 year study history chronic pancreatitis 8 . History alcohol abuse 9 . Have uncontrolled hypertriglyceridemia ( triglyceride &gt; 450 mg/dL ) 10 . Clinically significant , uncontrolled , active cardiovascular disease , specifically include , restrict : 1 . Myocardial infarction , within 6 month prior randomization 2 . Unstable angina within 6 month prior randomization 3 . Congestive heart failure within 6 month prior randomization 4 . History clinically significant ( determined treat physician ) atrial arrhythmia ventricular arrhythmia 5 . Any history ventricular arrhythmia 6 . Cerebrovascular accident transient ischemic attack within 6 month prior randomization 7 . Any history peripheral arterial occlusive disease require revascularization 8 . Any history venous thromboembolism include deep venous thrombosis pulmonary embolism 11 . Uncontrolled hypertension ( diastolic blood pressure &gt; 90 mm Hg ; systolic &gt; 140 mm Hg ) . Patients hypertension treatment study entry effect blood pressure control 12 . Taking medication know associated Torsades de Pointes 13 . Ongoing active infection . The requirement intravenous ( IV ) antibiotic consider active infection 14 . Known history human immunodeficiency virus ( HIV ) . Testing required absence history 15 . Pregnant breastfeed 16 . Malabsorption syndrome gastrointestinal illness could affect oral absorption study drug 17 . Diagnosed received anticancer therapy another primary malignancy within 3 year prior entry ( except nonmelanoma skin cancer cervical cancer situ ) 18 . Any condition illness , opinion Investigator , would compromise patient safety interfere evaluation drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Leukemia , Myeloid</keyword>
	<keyword>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</keyword>
	<keyword>Neoplasms Histologic Type</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>Lymphoproliferative Disorders</keyword>
	<keyword>Lymphatic Diseases</keyword>
	<keyword>Immunoproliferative Disorders</keyword>
	<keyword>Immune System Diseases</keyword>
	<keyword>Myeloproliferative Disorders</keyword>
	<keyword>Bone Marrow Diseases</keyword>
	<keyword>Hematologic Diseases</keyword>
</DOC>